Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index 18.5-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- FIASP (Type: EXPERIMENTAL): Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
- NovoRapid® (Type: ACTIVE_COMPARATOR): Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).